SCHEMBL3662804

SCHEMBL3662804

c1ccc(CNc2cc(-c3cccnc3)cc(-c3ccccn3)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.58
CYP1A2 P05177 6/20 0.58
CYP2D6 P10635 6/20 0.58
CLK4 Q9HAZ1 5/20 0.58
ALDH1A1 P00352 5/20 0.58
HSD17B10 Q99714 4/20 0.58
CYP2C19 P33261 5/20 0.56
USP2 O75604 3/20 0.56
GPR39 O43194 3/20 0.52
HIF1A Q16665 3/20 0.51
ALOX15 P16050 2/20 0.48
CYP2A6 P11509 1/20 0.48
LMNA P02545 2/20 0.47
MAPK1 P28482 2/20 0.47
GPR55 Q9Y2T6 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 1/20 0.47
FABP1 P07148 1/20 0.47
FABP6 P51161 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3664081 0.85 GPR39 (0.49) CYP3A4CYP1A2CYP2D6CLK4ALDH1A1
SCHEMBL3664054 0.84 GPR39 (0.46) CYP3A4CYP1A2CYP2D6CLK4ALDH1A1
SCHEMBL2239929 0.83 CYP3A4 (0.65) CYP3A4CYP1A2CYP2D6CLK4ALDH1A1
SCHEMBL3665841 0.81 CLK4 (0.55) CYP3A4CYP1A2CYP2D6CLK4ALDH1A1
SCHEMBL3669694 0.81 CYP2A6 (0.54) CYP3A4CYP1A2ALDH1A1CYP2A6CYP19A1
SCHEMBL3664008 0.80 PTGDR (0.47) CLK4ALDH1A1HIF1ACYP2A6MAPK1
SCHEMBL4775842 0.79 CYP3A4 (0.60) CYP3A4CYP1A2CYP2D6CLK4ALDH1A1
SCHEMBL3721234 0.78 CYP3A4 (0.41) CYP3A4CYP1A2CYP2D6CLK4ALDH1A1
SCHEMBL3664970 0.78 HDAC1 (0.43) CYP3A4CYP1A2CYP2D6CLK4ALDH1A1
SCHEMBL4775067 0.78 CYP3A4 (0.57) CYP3A4CYP1A2CYP2D6CLK4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK CYP3A4 1053/4885CYP1A2 616/4885CYP2D6 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.